Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3565 |
Name | meningioma |
Definition | A central nervous system cancer that are manifested in the central nervous system and arise from the arachnoid cap cells of the arachnoid villi in the meninges. |
Source | DiseaseOntology.org |
Alt Ids | DOID:3554 DOID:1137 DOID:3567 DOID:4750 |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer meningioma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 wild-type | CEP1347 | meningioma | sensitive | detail... |
PTEN loss | Bevacizumab + Everolimus | meningioma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01880749 | Phase I | Everolimus | Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas | Completed | USA | 0 |
NCT01967823 | Phase II | Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | Completed | USA | 0 |
NCT02282917 | Phase I | REC-2282 | Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma | Terminated | USA | 0 |
NCT02423525 | Phase I | Afatinib | Safety Study of Afatinib for Brain Cancer | Completed | USA | 0 |
NCT02523014 | Phase II | Abemaciclib GSK2256098 Vismodegib Capivasertib | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Recruiting | USA | 0 |
NCT02648997 | Phase II | Nivolumab | A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma | Active, not recruiting | USA | 0 |
NCT02831257 | Phase II | Vistusertib | AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas | Completed | USA | 0 |
NCT02847559 | Phase II | Bevacizumab | Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | Unknown status | USA | 0 |
NCT02933736 | Phase 0 | Ribociclib | Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients | Active, not recruiting | USA | 0 |
NCT03071874 | Phase II | Vistusertib | Phase II Study Of Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas | Unknown status | USA | 0 |
NCT03095248 | Phase II | Selumetinib | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601) | Completed | USA | 0 |
NCT03173950 | Phase II | Nivolumab | Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers | Recruiting | USA | 0 |
NCT03220646 | Phase II | Abemaciclib | Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | Active, not recruiting | USA | 0 |
NCT03267836 | Phase I | Avelumab | Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma | Terminated | USA | 0 |
NCT03279692 | Phase II | Pembrolizumab | Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma | Active, not recruiting | USA | 0 |
NCT03604978 | Phase Ib/II | Ipilimumab + Nivolumab Nivolumab | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Participants With Recurrent Grade II-III Meningioma | Suspended | USA | 0 |
NCT03631953 | Phase I | Alpelisib + Trametinib | Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas (ALTREM) | Recruiting | FRA | 0 |
NCT03971461 | Phase II | lutetium Lu 177 dotatate | Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma | Active, not recruiting | USA | 0 |
NCT04082520 | Phase II | lutetium Lu 177 dotatate | Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy | Recruiting | USA | 0 |
NCT04283669 | Phase II | Crizotinib | Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110) | Active, not recruiting | USA | 0 |
NCT04374305 | Phase II | Brigatinib | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) (INTUITT-NF2) | Recruiting | USA | 0 |
NCT04541082 | Phase I | ONC206 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | Recruiting | USA | 0 |
NCT04659811 | Phase II | Pembrolizumab | Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma | Recruiting | USA | 0 |
NCT05130866 | Phase II | REC-2282 | Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas (POPLAR-NF2) | Recruiting | USA | 0 |
NCT05228015 | Phase I | IK-930 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | GBR | 0 |
NCT05425004 | Phase II | Cabozantinib | Cabozantinib for Patients With Recurrent or Progressive Meningioma | Recruiting | USA | 0 |
NCT05940493 | Phase II | Abemaciclib | Abemaciclib in Newly Diagnosed Meningioma Patients | Not yet recruiting | USA | 0 |
NCT06012929 | Phase I | ONC201 | A Study of ONC201 for Refractory Meningioma | Not yet recruiting | USA | 0 |
NCT06126588 | Phase II | Everolimus | Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial (ELUMEN) | Not yet recruiting | FRA | 0 |
NCT06275919 | Phase II | Regorafenib | Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial) (MIRAGE) | Recruiting | ITA | 0 |